Table of Contents
ISRN Pharmacology
Volume 2012 (2012), Article ID 590626, 12 pages
http://dx.doi.org/10.5402/2012/590626
Review Article

Pharmacodynamic Modelling of Biomarker Data in Oncology

Pharmacometrics Ltd., Whittlesford, Cambridge CB22 4NZ, UK

Received 5 November 2011; Accepted 6 December 2011

Academic Editors: S. Cuzzocrea and E. M. Urbanska

Copyright © 2012 Robert C. Jackson. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Sarker and P. Workman, “Pharmacodynamic biomarkers for molecular cancer therapeutics,” Advances in Cancer Research, vol. 96, pp. 213–268, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. D. S. W. Tan, G. V. Thomas, M. D. Garrett et al., “Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development,” Cancer Journal, vol. 15, no. 5, pp. 406–420, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. Q. Zhou and J. M. Gallo, “The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic,” AAPS Journal, vol. 13, no. 1, pp. 111–120, 2011. View at Publisher · View at Google Scholar · View at PubMed
  4. R. J. Keizer, J. H. M. Schellens, J. H. Beijnen, and A. D. R. Huitema, “Pharmacodynamic biomarkers in model-based drug development in oncology,” Current Clinical Pharmacology, vol. 6, no. 1, pp. 30–40, 2011. View at Publisher · View at Google Scholar
  5. A. Sharma and W. J. Jusko, “Characterization of four basic models of indirect pharmacodynamic responses,” Journal of Pharmacokinetics and Biopharmaceutics, vol. 24, no. 6, pp. 611–635, 1996. View at Publisher · View at Google Scholar · View at Scopus
  6. R. C. Jackson, Computer Techniques in Preclinical and Clinical Drug Development, CRC Press, Boca Raton, Fla, USA, 1996.
  7. I. Rafi, G. A. Taylor, J. A. Calvete et al., “Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion,” Clinical Cancer Research, vol. 1, no. 11, pp. 1275–1284, 1995. View at Google Scholar · View at Scopus
  8. J. E. Kalns, N. J. Millenbaugh, M. G. Wientjes, and J. L. S. Au, “Design and analysis of in vitro antitumor pharmacodynamic studies,” in Proceedings of the American Association for Cancer Research, vol. 36, 1995, abstract no. 279.
  9. P. Jordan and R. Gieschke, “Explicit solutions for a class of indirect pharmacodynamic response models,” Computer Methods and Programs in Biomedicine, vol. 77, no. 2, pp. 91–97, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. E. F. Choo, M. Belvin, J. Chan et al., “Preclinical disposition and pharmacokinetics-pharmacodynamic modeling of biomarker response and tumour growth inhibition in xenograft mouse models of G-573, a MEK inhibitor,” Xenobiotica, vol. 40, no. 11, pp. 751–762, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. D. P. Lane, “Oncogenic intelligence: cell immortalization and transformation by the p53 gene,” Nature, vol. 312, no. 5995, pp. 596–597, 1984. View at Publisher · View at Google Scholar · View at Scopus
  12. B. D. Aguda and Y. Tang, “The kinetic origins of the restriction point in the mammalian cell cycle,” Cell Proliferation, vol. 32, no. 5, pp. 321–335, 1999. View at Google Scholar · View at Scopus
  13. P. Duesberg, R. Li, A. Fabarius, and R. Hehlmann, “Aneuploidy and cancer: from correlation to causation,” Contributions to Microbiology, vol. 13, pp. 16–44, 2006. View at Google Scholar
  14. F. Lévi, A. Altinok, and A. Goldbeter, “Circadian rhythms and cancer chronotherapeutics,” in Cancer Systems Biology, Bioinformatics and Medicine, A. Cesario and F. Marcus, Eds., pp. 381–407, Springer, Dordrecht, The Netherlands, 2011. View at Google Scholar
  15. B. Novák and J. J. Tyson, “A model for restriction point control of the mammalian cell cycle,” Journal of Theoretical Biology, vol. 230, no. 4, pp. 563–579, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at MathSciNet · View at Scopus
  16. C. Chassagnole, R. C. Jackson, N. Hussain et al., “Using a mammalian cell cycle simulation to interpret differential kinase inhibition in anti-tumour pharmaceutical development,” BioSystems, vol. 83, no. 2-3, pp. 91–97, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. C. Gérard and A. Goldbeter, “Temporal self-organization of the cyclin/Cdk network driving the mammalian cell cycle,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 51, pp. 21643–21648, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. D. Gilbert, H. Fuß, X. Gu et al., “Computational methodologies for modelling, analysis and simulation of signalling networks,” Briefings in Bioinformatics, vol. 7, no. 4, pp. 339–353, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. R. P. Araujo, E. F. Petricoin, and L. A. Liotta, “A mathematical model of combination therapy using the EGFR signaling network,” BioSystems, vol. 80, no. 1, pp. 57–69, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. F. A. Brightman and D. A. Fell, “Differential feedback regulation of the MAPK cascade underlies the quantitative differences in EGF and NGF signalling in PC12 cells,” FEBS Letters, vol. 482, no. 3, pp. 169–174, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Y. Shin, O. Rath, A. Zebisch, S. M. Choo, W. Kolch, and K. H. Cho, “Functional roles of multiple feedback loops in extracellular signal-regulated kinase and Wnt signaling pathways that regulate epithelial-mesenchymal transition,” Cancer Research, vol. 70, no. 17, pp. 6715–6724, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. M. Fussenegger, J. E. Bailey, and J. Varner, “A mathematical model of caspase function in apoptosis,” Nature Biotechnology, vol. 18, no. 7, pp. 768–774, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. F. Hua, M. G. Cornejo, M. H. Cardone, C. L. Stokes, and D. A. Lauffenburger, “Effects of Bcl-2 levels on fas signaling-induced caspase-3 activation: molecular genetic tests of computational model predictions,” Journal of Immunology, vol. 175, no. 2, pp. 985–995, 2005. View at Google Scholar · View at Scopus
  24. M. Bentele, I. Lavrik, M. Ulrich et al., “Mathematical modeling reveals threshold mechanism in CD95-induced apoptosis,” Journal of Cell Biology, vol. 166, no. 6, pp. 839–851, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. M. A. J. Chaplain and A. R. A. Anderson, “Mathematical modelling, simulation and prediction of tumour-induced angiogenesis,” Invasion and Metastasis, vol. 16, no. 4-5, pp. 222–234, 1996. View at Google Scholar · View at Scopus
  26. R. C. Jackson, Theoretical Foundations of Cancer Chemotherapy Introduced by Computer Models, Academic Press, San Diego, Calif, USA, 1992.
  27. T. Eissing, L. Kuepfer, C. Becker et al., “A computational systems biology software platform for multiscale modelling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks,” Frontiers in Physiology, vol. 2, article 4, 2011. View at Google Scholar
  28. R. C. Jackson, “Predictive software for drug design and development: recent progress and future developments,” Pharmaceutical Development & Regulation, vol. 1, pp. 159–168, 2003. View at Google Scholar
  29. B. Basse, B. C. Baguley, E. S. Marshall et al., “Modelling cell death in human tumour cell lines exposed to the anticancer drug paclitaxel,” Journal of Mathematical Biology, vol. 49, no. 4, pp. 329–357, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at MathSciNet · View at Scopus
  30. B. Basse, W. R. Joseph, E. S. Marshall, and B. C. Baguley, “Analysis of radiation-induced changes to human melanoma cultures using a mathematical model,” Cell Proliferation, vol. 43, no. 2, pp. 139–146, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. J. M. Hou, A. Greystoke, L. Lancashire et al., “Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy,” American Journal of Pathology, vol. 175, no. 2, pp. 808–816, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. W. S. Hsieh, B. K. Peh, T. Loh et al., “Pharmacodynamic effects of seliciclib (R-roscovitine, CYC202) in patients with undifferentiated nasopharyngeal carcinoma (NPC) using a window trial design,” in EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics, 2006, abstract no. 279.
  33. S. Iadevaia, Y. Lu, F. C. Morales, G. B. Mills, and P. T. Ram, “Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis,” Cancer Research, vol. 70, no. 17, pp. 6704–6714, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. F. R. Luo, Z. Yang, A. Camuso et al., “Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure,” Clinical Cancer Research, vol. 12, no. 23, pp. 7180–7186, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. S. Yamazaki, J. Skaptason, D. Romero et al., “Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models,” Drug Metabolism and Disposition, vol. 36, no. 7, pp. 1267–1274, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. L. Lee, H. Niu, R. Rueger et al., “The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of CH4987655 in healthy volunteers: target suppression using a biomarker,” Clinical Cancer Research, vol. 15, no. 23, pp. 7368–7374, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. L. Salphati, H. Wong, M. Belvin et al., “Pharmacokinetic-pharmacodynamic modelling of tumor growth inhibition and biomarker modulation by the novel phosphoinositol 3-kinase inhibitor GDC-0941,” Drug Metabolism and Disposition, vol. 38, pp. 1436–1442, 2010. View at Google Scholar
  38. H. B. Mistry, R. C. Jackson, M. A. J. Chaplain, and F. A. Davidson, “A pharmacodynamic model of the mitotic spindle checkpoint and the action of aurora kinase inhibitors,” in Proceedings of the 99th Annual Meeting of the American Association for Cancer Research (AACR '08), San Diego, Calif, USA, April 2008, abstract no. 1642.
  39. C. Chassagnole, E. Fernandez, F. Scaerou et al., “Systems biology analysis of a novel aurora kinase inhibitor: CYC116,” in Proceedings of the Proceedings of the American Association for Cancer Research, 2008, abstract no. 1645.
  40. H. B. Mistry, D. E. MacCallum, R. C. Jackson, M. A. J. Chaplain, and F. A. Davidson, “Modeling the temporal evolution of the spindle assembly checkpoint and role of Aurora B kinase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 51, pp. 20215–20220, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. M. Hajduch, D. Vydra, P. Dzubak, M. Dziechciarkova, I. Stuart, and D. Zheleva, “In vivo mode of action of CYC116, a novel small molecule inhibitor of aurora kinases and VEGFR2,” in Proceedings of the American Association for Cancer Research, 2008, abstract no. 5645.
  42. H. B. Mistry, D. E. MacCallum, R. C. Jackson, M. A. Chaplain, and F. A. Davidson, “A pharmacodynamic model of Aurora kinase inhibitors in the spindle assembly checkpoint,” Frontiers in Bioscience, vol. 15, pp. 249–258, 2010. View at Google Scholar · View at Scopus
  43. H. Kamei, R. C. Jackson, D. Zheleva, and F. A. Davidson, “An integrated pharmacokinetic-pharmacodynamic model for an Aurora kinase inhibitor,” Journal of Pharmacokinetics and Pharmacodynamics, vol. 37, no. 4, pp. 407–434, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. A. Lindauer, P. Di Gion, F. Kanefendt et al., “Pharmacokinetic/pharmacodynamic modelling of biomarker response to sunitinib in healthy volunteers,” Clinical Pharmacology and Therapeutics, vol. 87, pp. 601–608, 2010. View at Google Scholar
  45. A. Greystoke, J. P. B. O'Connor, K. Linton et al., “Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma,” British Journal of Cancer, vol. 104, no. 4, pp. 719–725, 2011. View at Publisher · View at Google Scholar · View at PubMed
  46. E. C. de Haas, A. Di Pietro, K. L. Simpson et al., “Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomakers in a drug-sensitive tumor, testicular cancer,” Neoplasia, vol. 10, no. 10, pp. 1041–1048, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. T. H. Ward, J. Cummings, E. Dean et al., “Biomarkers of apoptosis,” British Journal of Cancer, vol. 99, no. 6, pp. 841–846, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. S. Linder, A. M. Havelka, T. Ueno, and M. C. Shoshan, “Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker,” Cancer Letters, vol. 214, no. 1, pp. 1–9, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. T. Ueno, M. Toi, and S. Linder, “Detection of epithelial cell death in the body by cytokeratin 18 measurement,” Biomedicine and Pharmacotherapy, vol. 59, supplement 2, pp. S359–S362, 2005. View at Publisher · View at Google Scholar
  50. S. Linder, “Cytokeratin markers come of age,” Tumor Biology, vol. 28, no. 4, pp. 189–195, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. V. Barak, H. Goike, K. W. Panaretakis, and R. Einarsson, “Clinical utility of cytokeratins as tumor markers,” Clinical Biochemistry, vol. 37, no. 7, pp. 529–540, 2004. View at Publisher · View at Google Scholar · View at PubMed
  52. S. Linder, M. H. Olofsson, R. Herrmann, and E. Ulukaya, “Utilization of cytokeratin-based biomarkers for pharmacodynamic studies,” Expert Review of Molecular Diagnostics, vol. 10, no. 3, pp. 353–359, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. J. Cummings, M. Ranson, E. Lacasse et al., “Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP,” British Journal of Cancer, vol. 95, no. 1, pp. 42–48, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. D. Micha, J. Cummings, A. Shoemaker et al., “Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer,” Clinical Cancer Research, vol. 14, no. 22, pp. 7304–7310, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. J. Cummings, C. Hodgkinson, R. Odedra et al., “Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity,” Molecular Cancer Therapeutics, vol. 7, no. 3, pp. 455–463, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. M. H. Olofsson, J. Cummings, W. Fayad et al., “Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarker,” Cancer Biomarkers, vol. 5, no. 3, pp. 117–125, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. E. J. Dean, J. Cummings, A. Roulston et al., “Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer,” Neoplasia, vol. 13, no. 4, pp. 339–347, 2011. View at Publisher · View at Google Scholar
  58. C. Dive, R. A. Smith, E. Garner et al., “Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer,” British Journal of Cancer, vol. 102, no. 3, pp. 577–582, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. S. R. Green, S. Frame, I. Fleming et al., “Identification of pharmacodynamic markers to support clinical trials of CYC202 (R-roscovitine), a cyclin-dependent kinase inhibitor,” in Proceedings of the American Association for Cancer Research, vol. 44, 2003, abstract no. 2967.
  60. S. R. Green, S. Frame, K. Watt et al., “Identification of clinically relevant pharmacodynamic biomarkers in patients treated with the cdk inhibitor CYC202 (R-roscovitine),” in EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics, 2004, abstract no. 432.
  61. S. Frame, S. Anderson, K. Watt et al., “Identification and clinical validation of biomarkers to support the development of seliciclib (CYC202),” in Proceedings of the American Association for Cancer Research, vol. 46, 2005, abstract no. 460.
  62. D. E. MacCallum, J. Melville, S. Frame et al., “Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1,” Cancer Research, vol. 65, no. 12, pp. 5399–5407, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. R. C. Jackson, A. L. Barnett, S. J. McClue, and S. R. Green, “Seliciclib, a cell-cycle modulator that acts through the inhibition of cyclin-dependent kinases,” Expert Opinion on Drug Discovery, vol. 3, no. 1, pp. 131–143, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. J. Cummings, C. Zhou, and C. Dive, “Application of the β-expectation tolerance interval to method validation of the M30 and M65 ELISA cell death biomarker assays,” Journal of Chromatography B, vol. 879, no. 13-14, pp. 887–893, 2011. View at Publisher · View at Google Scholar · View at PubMed
  65. L. J. Lancashire, D. L. Roberts, C. Dive, and A. G. Renehan, “The development of composite circulating biomarker models for use in anticancer drug clinical development,” International Journal of Cancer, vol. 128, no. 8, pp. 1843–1851, 2011. View at Publisher · View at Google Scholar · View at PubMed
  66. S. de la Motte and A. Gianella-Borradori, “Pharmacokinetic model of R-roscovitine and its metabolite in health male subjects,” International Journal of Clinical Pharmacology and Therapeutics, vol. 42, no. 4, pp. 232–239, 2004. View at Google Scholar · View at Scopus
  67. P. Wells, E. Aboagye, R. N. Gunn et al., “2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337,” Journal of the National Cancer Institute, vol. 95, no. 9, pp. 675–682, 2003. View at Google Scholar · View at Scopus
  68. P. Workman, E. O. Aboagye, Y. L. Chung et al., “Minimally invasive Pharmacokinetic and Pharmacodynamic Technologies in hypothesis-testing clinical trials of innovative therapies,” Journal of the National Cancer Institute, vol. 98, no. 9, pp. 580–598, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. Y. L. Chung, H. Troy, R. Kristeleit et al., “Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts,” Neoplasia, vol. 10, no. 4, pp. 303–313, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. M. Beloueche-Babari, Y. L. Chung, N. M. S. Al-Saffar, M. Falck-Miniotis, and M. O. Leach, “Metabolic assessment of the action of targeted cancer therapeutics using magnetic resonance spectroscopy,” British Journal of Cancer, vol. 102, no. 1, pp. 1–7, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  71. C. L. Mitchell, J. P. B. O'connor, A. Jackson et al., “Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy,” Annals of Oncology, vol. 21, no. 10, pp. 1982–1989, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  72. E. T. McKinley, J. E. Bugaj, P. Zhao et al., “18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer,” Clinical Cancer Research, vol. 17, no. 10, pp. 3332–3340, 2011. View at Publisher · View at Google Scholar · View at PubMed
  73. W. R. Greco and R. C. Jackson, “Prediction of the in vivo and clinical activity of drug combinations from in vitro data by differential pharmacodynamics,” in Proceedings of the American Association for Cancer Research, 2008, abstract no. 4765.
  74. D. Orrell and E. Fernandez, “Using predictive mathematical models to optimise the scheduling of anti-cancer drugs,” Innovations in Pharmaceutical Technology, no. 33, pp. 58–62, 2010. View at Google Scholar · View at Scopus
  75. D. Orrell, E. Fernandez, D. Cronier et al., “Predicting the effect of combination schedules on xenograft tumor using the Virtual Tumor,” in Proceedings of the American Association for Cancer Research, 2011, abstract no. 4918.
  76. P. Girard, M. Cucherat, and D. Guez, “Clinical trial simulation in drug development,” Therapie, vol. 59, no. 3, pp. 287–304, 2004. View at Publisher · View at Google Scholar · View at Scopus
  77. C. Snell, D. Orrell, E. Fernandez, C. Chassagnole, and D. Fell, “Systems biology approaches to cancer drug development,” in Cancer Systems Biology, Bioinformatics and Medicine, A. Cesario and F. Marcus, Eds., pp. 367–380, Springer, Dordrecht, The Netherlands, 2011. View at Google Scholar
  78. D. Ternant, E. Hénin, G. Cartron, M. Tod, G. Paintaud, and P. Girard, “Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma,” British Journal of Clinical Pharmacology, vol. 68, no. 4, pp. 561–573, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. S. Yamazaki, L. Nguyen, S. Vekich et al., “Pharmacokinetic/pharmacodynamic response modelling of biomarker and tumor growth inhibition to an orally available heat shock protein 90 inhibitor in human tumor xenograft mouse model,” Journal of Pharmacology and Experimental Therapeutics, vol. 338, no. 3, pp. 964–973, 2011. View at Google Scholar